Trial Profile
LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms LEEomic
- Sponsors Novartis Pharmaceuticals
- 02 Mar 2021 Status changed from recruiting to completed.
- 18 May 2020 Planned End Date changed from 30 Dec 2019 to 30 Dec 2020.
- 18 May 2020 Planned primary completion date changed from 28 Dec 2019 to 30 Dec 2020.